ArticleHuman brain mapping2015
Dopaminergic correlates of metabolic network activity in Parkinson's disease.
Article in Human brain mapping, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis.NeuroImage. Clinical · 2019Pooled it
- Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020Trial
- Different brain spatial metabolic patterns characterizing different subtypes of multiple system atrophy.Journal of Parkinson's disease · 2026Article
- Brain Network Patterns in Patients With Multiple System Atrophy: Spatial Independent Component Analysis Using FDG-PET Data.Neurology · 2026Article
- Association of dopamine depletion and cholinergic basal forebrain atrophy with brain metabolism and cognition in Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.Movement disorders : official journal of the Movement Disorder Society · 2025Review
- A Narrative Review on Biochemical Markers and Emerging Treatments in Prodromal Synucleinopathies.Clinics and practice · 2025Review
- Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [NPJ Parkinson's disease · 2024Article
- Article
- Covering Basic Needs on Molecular Imaging.Movement disorders clinical practice · 2024Article
- Functional Brain Networks to Evaluate Treatment Responses in Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- The reconfiguration pattern of individual brain metabolic connectome for Parkinson's disease identification.MedComm · 2023Article
- Microglia and Astrocytes Dysfunction and Key Neuroinflammation-Based Biomarkers in Parkinson's Disease.Brain sciences · 2023Review
- Parkinson's disease progression: Increasing expression of an invariant common core subnetwork.NeuroImage. Clinical · 2023Article
- Seed-Based Connectivity Prediction of Initial Outcome of Subthalamic Nuclei Deep Brain Stimulation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms.Movement disorders clinical practice · 2022Review
- Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease.Molecular medicine (Cambridge, Mass.) · 2021Review
- Parkinson's disease-related pattern (PDRP) identified using resting-state functional MRI: Validation study.Neuroimage. Reports · 2021Article
- Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson's disease.Molecular medicine (Cambridge, Mass.) · 2021Review
- Modulating brain networks associated with cognitive deficits in Parkinson's disease.Molecular medicine (Cambridge, Mass.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is associated with distinct metabolic covariance patterns that relate to the motor and cognitive manifestations of the disorder. It is not known, however, how the expression of these patterns relates to measurements of nigrostriatal dopaminergic activity from the same individuals. To explore these associations, we studied 106 PD subjects who underwent cerebral PET with both (18) F-fluorodeoxyglucose (FDG) and (18) F-fluoro-L-dopa (FDOPA). Expression values for the PD motor- and cognition-related metabolic patterns (PDRP and PDCP, respectively) were computed for each subject; these measures were correlated with FDOPA uptake on a voxel-by-voxel basis. To explore the relationship between dopaminergic function and local metabolic activity, caudate and putamen FDOPA PET signal was correlated voxel-wise with FDG uptake over the entire brain. PDRP expression correlated with FDOPA uptake in caudate and putamen (P < 0.001), while PDCP expression correlated with uptake in the anterior striatum (P < 0.001). While statistically significant, the correlations were only of modest size, accounting for less than 20% of the overall variation in these measures. After controlling for PDCP expression, PDRP correlations were significant only in the posterior putamen. Of note, voxel-wise correlations between caudate/putamen FDOPA uptake and whole-brain FDG uptake were significant almost exclusively in PDRP regions. Overall, the data indicate that PDRP and PDCP expression correlates significantly with PET indices of presynaptic dopaminergic functioning obtained in the same individuals. Even so, the modest size of these correlations suggests that in PD patients, individual differences in network activity cannot be explained solely by nigrostriatal dopamine loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.